David Adams, PhD
Senior Group Leader and Head of Experimental Cancer Genetics, Wellcome Trust Sanger Institute
David Adams, PhD
Senior Group Leader and Head of Experimental Cancer Genetics, Wellcome Trust Sanger Institute
David Adams is a senior group leader in the Cancer Ageing and Somatic Mutation programme at the Wellcome Sanger Institute and leads the Experimental Cancer Genetics Laboratory. He is a Fellow of the Academy of Medical Sciences and the Royal College of Pathologists, the chair of the Scientific Advisory Board (SAB) of Beatson Institute, and a member of the SAB of the International Laboratory of Human Genome Research.
He is also a founding member of the Atlas of Variant Effects Consortium and a member of the steering committee of the Society for Melanoma Research, and co-chairs Genomel (The Genetics of Melanoma Consortium). His group uses large-scale genomic studies and genome editing to identify cancer genes and explore their function. They also explore host-tumour interactions.
Dave is co-head of the Sanger Excellence Programme for Black British scientist (with Dr. Saher Ahmed) and is involved in advocacy efforts for cancer genetic studies in LMICs, particularly with Latin American countries, work which is funded by the MRC and Royal Society.
Professor Paolo A. Ascierto
Professor of Medicine, Board Certified in Oncology
Professor Paolo A. Ascierto
Professor of Medicine, Board Certified in Oncology
Paolo Ascierto is Director of the Department of Skin Cancers, Cancer Immunotherapy and Innovative Therapeutics at the National Tumour Institute “Fondazione G. Pascale” in Naples, Italy.
Paolo’s major research interests are the molecular biology of skin cancers, the assessment of molecular markers for tumour progression in melanoma, biochemical and immunological monitoring, targeted therapies for melanoma, vaccination treatments and immunotherapy of solid tumours, and combination approaches for cancer treatment.
Paolo is an active member of the European Society for Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO), and the Society for Immunotherapy of Cancer (SITC). He has presided as Principal and Lead Investigator on over 160 clinical trials and is the author of 650+ publications in major peer-reviewed journals.
Pippa Corrie, PhD, FRCP
Affiliated Associate Professor of Medical Oncology, University of Cambridge, UK
Pippa Corrie, PhD, FRCP
Affiliated Associate Professor of Medical Oncology, University of Cambridge, UK
Pippa Corrie is Medical Oncologist at Cambridge University Hospitals National Health Service (NHS) Foundation Trust at Addenbrooke’s Hospital in Cambridge, UK, Co-Lead at the National Institute for Health and Care Research (NIHR) Cancer National Specialty and Vaccines Research Programme, and NIHR Clinical Research Network (CRN) National Specialty Lead for Cancer in late-phase and international trials.
Pippa is recognised internationally as a leading melanoma and pancreatic cancer specialist. She is Chief Principal Investigator of the UK MITRE (Microbiome Immunotherapy Toxicity and Response Evaluation) study involving Microbiotica, recruiting melanoma, renal and lung cancer patients receiving immune checkpoint inhibitors at multiple UK sites. She has published widely in both clinical and translational cancer research.
Pippa is closely involved in patient advocacy, being a co-founder and trustee of the UK Melanoma Focus charity and supporting consumer involvement with charities including Pancreatic Cancer UK and Cancer Research UK.
Supporting our MB310 inflammatory bowel disease development programme
Professor Walter Reinisch
Professor for Gastroenterology and Hepatology at Vienna Medical University, Austria
Professor Walter Reinisch
Professor for Gastroenterology and Hepatology at Vienna Medical University, Austria
Walter Reinisch is the Director of the Inflammatory Bowel Disease Study Group at the Medical University of Vienna, Austria. He is a founding member of the European Crohn’s and Colitis Organisation (ECCO) and was assigned as an honorary member after having contributed in various positions. He is also a member of the International Organisation for the Study of Inflammatory Bowel Disease (IOIBD).
Walter was an active member of the Scientific and Public Affairs Committee of the United European Gastroenterology (UEG) organisation and headed the Austrian Inflammatory Bowel Disease Study Group. Previously, he held the Audrey Campbell Chair in Ulcerative Colitis Research at McMaster University, Ontario, Canada from 2013 to 2016.
Bruce E. Sands, MD, MS
Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Bruce E. Sands, MD, MS
Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Bruce Sands is System Chief, Division of Gastroenterology, Mount Sinai Health, New York, USA. He is an expert in the management of Inflammatory Bowel Diseases (IBD) and has earned an international reputation for caring for patients with complex and refractory disease.
Bruce was awarded his BA and MD from Boston University, USA, and trained in internal medicine at the Hospital of the University of Pennsylvania, PA, USA. After completing a GI fellowship at the Massachusetts General Hospital (MGH) in Boston, MA, USA he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.
Bruce is a past chair of the Clinical Research Alliance of the Crohn's and Colitis Foundation of America and was Chair of the Immunology, Microbiology, and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, he was the Chair of the International Organisation for the Study of IBD (IOIBD).
Bruce has served as an Associate Editor for Gastroenterology and published nearly 300 original manuscripts in leading medical journals.
Professor Herbert Tilg
Professor of Medicine, Medical University Innsbruck, Austria
Professor Herbert Tilg
Professor of Medicine, Medical University Innsbruck, Austria
Herbert Tilg is Head of the Department of Gastroenterology, Hepatology & Endocrinology at the Medical University of Innsbruck, Austria. His research is focused on inflammation and cytokines in gastrointestinal disorders.
Herbert did his research fellowship at Tufts University, MA, USA, with Charles Dinarello, distinguished professor of medicine and an expert on inflammatory cytokines.
Herbert served as a member of the Governing Board of the European Crohn’s and Colitis Organisation (ECCO), the European Association for the Study of the Liver (EASL), and the United European Gastroenterology (UEG), a leading authority of gastrointestinal health. He was Chairman of the Scientific Committee of UEG and is currently Associate Editor for the major gastrointestinal Journal GUT.
Professor Séverine Vermeire
Full Professor of Medicine at the Catholic University (KU) Leuven
Professor Séverine Vermeire
Full Professor of Medicine at the Catholic University (KU) Leuven
Séverine Vermeire is a staff member at the Gastroenterology and Hepatology Department of the University Hospital Leuven, Belgium. She is also the Research Director of Biomedical Sciences at KU Leuven.
Séverine is principal and lead investigator in numerous randomised controlled trials with new therapeutic compounds. Her scientific work has resulted in more than 600 peer-reviewed articles and focuses on the role of the microbiome and genetic susceptibility in Inflammatory Bowel Disease (IBD) and on identifying prognostic and predictive signatures of treatment response. She has participated in the International Consortium for Health Outcomes Measurement (ICHOM) Conference developing Patient-Centered Outcomes for Inflammatory Bowel Disease.
Séverine was awarded an Advanced H2020-European Research Council (ERC) Grant (2016-2022) and was President of the European Crohn’s and Colitis Organisation (ECCO) from 2014-2016 and of the Belgian IBD Research and Development (BIRD) Group from 2011-2013.
